Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

NCT04140162 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.

NCT NCT04140162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04140162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
Lead sponsor
University of Michigan Rogel Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 5, 2020
Completion date
September 2, 2026
Enrollment
57 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma